Familial Hypercholesterolemia
Symptoms, Doctors, Treatments, Advances & More

Familial Hypercholesterolemia Overview

Save information for later
Sign Up

Learn About Familial Hypercholesterolemia

View Main Condition: High Cholesterol

What is the definition of Familial Hypercholesterolemia?
Familial hypercholesterolemia is a common genetic condition that causes high blood levels of low-density lipoprotein (LDL), or bad, cholesterol. This bad cholesterol builds up in the arteries, causing them to harden and narrow. Familial hypercholesterolemia increases the risks of cardiovascular disease and heart attack.
What are the symptoms of Familial Hypercholesterolemia?
Symptoms of familial hypercholesterolemia may not occur until an adult. If an individual inherits familial hypercholesterolemia from both parents, symptoms usually appear in childhood. Symptoms of familial hypercholesterolemia may include xanthelasmas (cholesterol lesions in the eyelids); a white or gray ring around the iris of the eye; xanthomas (fatty skin lesions) around the cornea and on the hands, elbows, buttocks, knees, and ankles; chest pain; stroke-like symptoms, such as speech difficulties, facial paralysis, arm or leg weakness, and loss of balance; calve cramping upon walking; cholesterol deposits in tendons; sores on toes; cerebrovascular disease; peripheral artery disease; transient ischemic attack; and stroke.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Familial Hypercholesterolemia?
Familial hypercholesterolemia in childhood that is left untreated can lead to death by age 20. However, the cardiovascular symptoms associated with familial hypercholesterolemia can be prevented with early treatment. Treatments for familial hypercholesterolemia include lifestyle modifications, such as a low-saturated fat diet, weight loss, and regular exercise; quitting smoking; medications, such as atorvastatin, Fluvastatin, lovastatin, pravastatin, pitivastatin, rosuvastatin, simvastatin, colesevalam, Welcol, bempedoic acid, icosapent ethyl, ezetimibe, fibrates, nicotinic acid, alirocumab, evinacumab-dgnb, evolocumab, lomitapide, and mipomersen; blood plasma-filtering (apharesis); and liver transplantation.
Who are the top Familial Hypercholesterolemia Local Doctors?
Distinguished in Familial Hypercholesterolemia
Dr. Charles D. Christian
Internal Medicine
Distinguished in Familial Hypercholesterolemia
Dr. Charles D. Christian
Internal Medicine
Before you request

IU Health Morgan Physicians LLC

820 N Samuel Moore Pkwy Ste B, 
Mooresville, IN 
317-483-5060
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Christian is a primary care provider, practicing in Internal Medicine in Mooresville, Indiana. Dr. Christian is rated as a Distinguished provider by MediFind in the treatment of Familial Hypercholesterolemia. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), and Defective Apolipoprotein B-100. Dr. Christian is currently accepting new patients.

Elite in Familial Hypercholesterolemia
Dr. Patrick M. Moriarty
Internal Medicine
Elite in Familial Hypercholesterolemia
Dr. Patrick M. Moriarty
Internal Medicine

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Moriarty is a primary care provider, practicing in Internal Medicine in Kansas City, Kansas. Dr. Moriarty is rated as an Elite provider by MediFind in the treatment of Familial Hypercholesterolemia. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses High Cholesterol, Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), and Defective Apolipoprotein B-100. Dr. Moriarty is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Familial Hypercholesterolemia
Elite in Familial Hypercholesterolemia
Referral may be required
Nagoya, JP 

Mika Hori practices practicing medicine in Nagoya, Japan. Hori is rated as an Elite expert by MediFind in the treatment of Familial Hypercholesterolemia. They are also highly rated in 9 other conditions, according to our data. Their clinical expertise encompasses Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, High Cholesterol, Defective Apolipoprotein B-100, and Pancreaticoduodenectomy.

View All Doctors
What are the latest Familial Hypercholesterolemia Clinical Trials?
A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Homozygous Familial Hypercholesterolemia With LDLR Mutations
A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Homozygous Familial Hypercholesterolemia With LDLR Mutations
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Genetic
Study Phase: Early Phase 1

Summary: This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR mutations. NGGT006 is an adeno-associated viral (AAV) vector carrying codon-optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoti...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol
Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating ...

View All Clinical Trials